EQRx chairman Alexis Borisy and CEO Melanie Nallichieri

EQRx, CStone un­furl full lung can­cer da­ta for PD-L1 drug in what the part­ners are call­ing a first

As a self-styl­ized drug pric­ing dis­rup­tor, EQRx has high hopes for its lead PD-(L)1 to of­fer proof of con­cept for the en­tire busi­ness mod­el. Af­ter tout­ing a win back in May, the biotech is back with full da­ta in lung can­cer that could back up an ap­proval.

Pa­tients dosed with EQRx and CStone Phar­ma­ceu­ti­cals’ sug­e­mal­imab post­ed me­di­an pro­gres­sion-free sur­vival of 9 months com­pared with 5.8 months for pa­tients giv­en place­bo (p=0.0026), ac­cord­ing to full da­ta from the Phase III GEM­STONE-301 study in Stage III non-small cell lung can­cer set to be pre­sent­ed at this week­end’s #ES­MO21.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.